Protara Therapeutics, Inc.

Protara Therapeutics, Inc. reported a net loss of $57.4 million for fiscal year 2025, driven by total operating expenses of $64.5 million, primarily consisting of research and development ($42.6 million) and general and administrative ($21.9 million) costs. The company generated other income of $7.1 million, largely from interest and investment income ($6.4 million). Cash and cash equivalents decreased by $113.1 million to $50.4 million at year-end, despite raising $82.7 million from financing activities, including public offerings in December 2024 and 2025. The company's balance sheet shows total assets of $209.5 million, with stockholders' equity of $196.4 million and an accumulated deficit of $302.4 million. No revenue was reported for the period.

Key Takeaways